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Abstract 
Background: The reliable detection of SARS-CoV-2 has become one of the most important contributions to COVID-
19 crisis management. With the publication of the first sequences of SARS-CoV-2, several diagnostic PCR assays have 
been developed and published. In addition to in-house assays the market was flooded with numerous commercially 
available ready-to-use PCR kits, with both approaches showing alarming shortages in reagent supply.
Aim: Here we present a resource-efficient in-house protocol for the PCR detection of SARS-CoV-2 RNA in patient 
specimens (RKI/ZBS1 SARS-CoV-2 protocol).
Methods: Two duplex one-step real-time RT-PCR assays are run simultaneously and provide information on two dif-
ferent SARS-CoV-2 genomic regions. Each one is duplexed with a control that either indicates potential PCR inhibition 
or proves the successful extraction of nucleic acid from the clinical specimen.
Results: Limit of RNA detection for both SARS-CoV-2 assays is below 10 genomes per reaction. The protocol enables 
testing specimens in duplicate across the two different SARS-CoV-2 PCR assays, saving reagents by increasing testing 
capacity. The protocol can be run on various PCR cyclers with several PCR master mix kits.
Conclusion: The presented RKI/ZBS1 SARS-CoV-2 protocol represents a cost-effective alternative in times of short-
ages when commercially available ready-to-use kits may not be available or affordable.
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Background
The new coronavirus SARS-CoV-2 causing the disease 
COVID-19 was first described in China in the Hubei 
region at the end of 2019 and evolved into a pandemic 
within just a few weeks [1]. As with every new infec-
tious disease, the rapid and reliable identification of the 
causative agent is crucial to the management of dis-
eased patients. Thanks to the advent of Next-Generation 
Sequencing techniques the first full genome sequence of 
SARS-CoV-2 could be published only days after the 
first official reports of the new virus SARS-CoV-2 [2]. 
Besides several other aspects, the genomic sequence is 
fundamental to PCR-based diagnostics, and  its knowl-
edge enables the assessment of available PCR assays for 
closely related coronaviruses regarding their usefulness 
for SARS-CoV-2 detection and, in addition, allows the 
design of new, potentially more specific PCR assays [3]. 
For the diagnostics of several pathogens the real-time 
PCR has become the method of choice, being quick, 
reproducible, specific, safe and extremely sensitive with 
detection limits below 10 genome equivalents of a patho-
gen per reaction [4]. Therefore, it seems obvious that in 
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the recent SARS-CoV-2 pandemic, real-time PCR diag-
nostics was urgently needed [5].
Fortunately, as early as in mid-January 2020 a first cru-
cial real-time PCR system was published [6] and enabled 
several diagnostic PCR laboratories all over the world to 
identify SARS-CoV-2. Since then, many real-time PCR 
assays were shared in the diagnostics community or pub-
lished in appropriate journals, either as in-house assays 
or as commercially available ready-to-use kits with dif-
ferent levels of validation and certification [7]. Both the 
extensively validated in-house assays as well as the com-
mercial kits have their advantages and drawbacks [8, 9].
Ready-to-use kits that contain all reagents necessary 
for real-time PCR present the easiest approach to diag-
nostics, even for laboratories with little experience in 
virus diagnostics. These kits are sometimes well validated 
and can have a CE-label. Some include internal controls 
that check for successful nucleic acid extraction. For 
many laboratories, these ready-to-use kits can be a per-
fect solution. However, since in these kits the sequences 
of primers and probes are usually not released, the user 
is dependent on the manufacturer regarding the assay’s 
validity for new virus variants. Moreover, some kits are 
validated for specific real-time PCR instruments, restrict-
ing their use, which can be very costly and may become 
an issue for high throughput analyses. And most impor-
tant, in the course of the COVID-19 pandemic, several 
manufacturers had to cope with reagent shortages, lead-
ing in some cases to a halt in kit production.
On the other hand, in-house assays, that in principle 
require a higher expertise to be run routinely in high-
throughput, seem to be less susceptible to the problems 
mentioned above. In most regions of the world, various 
suppliers can provide primers and probes for real-time 
PCR. A variety of basic master mixes for PCR and one-
step RT-PCR can be obtained from an accordingly huge 
number of manufacturers. Knowledge of the primer 
and probe sequence provides some degree of flexibility 
in adjusting the sequences to newly occurring variants. 
And when considering the costs for the required indi-
vidual reagents, in-house assays are generally less costly 
than ready-to-use kits. However, the ongoing pandemic 
has been teaching us that oligo suppliers may also suffer 
from contamination problems and even established man-
ufacturers can run out of reagents, which poses a huge 
problem to diagnostic laboratories. Finally, the decision 
between ready-to-use kits and in-house reagents has to 
fit the individual circumstances.
Here we present the RKI/ZBS1 SARS-CoV-2 protocol 
that was developed to identify SARS-CoV-2 RNA reli-
ably by targeting two different genomic regions (E-Gene 
and orf1ab). Both were duplexed with newly designed 
PCR assays controlling for inhibition (KoMa) as well 
as successful nucleic acid extraction from respiratory 
specimens commonly taken for COVID-19 diagnostics 
(c-myc). While one of the SARS-CoV-2-specific PCRs has 
already been published [6], the second PCR was newly 
designed to be highly specific for SARS-CoV-2. The vali-
dation of this protocol is presented and the experience 
with the first 3600 analyzed specimens is used to describe 
and discuss pitfalls in the interpretation of results.
Material and methods
PCR design
The E-Gene assay was taken from [6]. The orf1ab assay 
was designed based on 72 available sequences at the time 
of design. Further sequences of coronaviruses, in particu-
lar SARS-CoV and the common cold causing coronavi-
ruses OC43, 229E, HKU-1 and NL-63, were included in 
the alignments to enable a SARS-CoV-2-specific design 
[10]. KoMa is an artificial sequence that has no signifi-
cant homology to any sequence in GenBank for which 
we have established various PCR assays. All assays were 
designed according to standard rules with the intention 
to avoid significant interaction in the established duplex 
PCRs representing the RKI/ZBS1 SARS-CoV-2 protocol 
and to run at 60 °C annealing temperature. Tables 1 and 2 
show the primer and probe sequences used.
Principle of the assays
The established RKI/ZBS1 SARS-CoV-2 protocol is a 
one-step real-time RT-PCR assay that consists of two 
independent PCR reactions. PCR 1 includes the already 
published E-Gene assay with a FAM-labeled probe, but 
is adapted to 60  °C annealing temperature. The E-Gene 
assay is duplexed with an assay to detect the artificial 
sequence KoMa which is added as VLP to the clinical 
specimen prior to nucleic acid extraction and ideally 
results in a CT value of approximately 32. A significant 
CT value shift for KoMa indicates PCR inhibition or inef-
ficient RNA extraction. The KoMa assay uses two prim-
ers and a Texas Red-labeled probe.
PCR 2 includes a PCR assay located in the orf1ab 
gene region with two primers and a FAM-labeled Minor 
Groove Binding (MGB) probe for SARS-CoV-2 detection. 
Based on this MGB probe, the orf1ab assay is highly spe-
cific for SARS-CoV-2. The orf1ab assay can be duplexed 
with an assay to detect human nucleic acid, DNA as well 
as RNA/cDNA, with two primers and a Cy5-labeled 
probe. In particular for SARS-CoV-2-negative specimens, 
the proof of nucleic acid in the PCR reaction is unequivo-
cal to exclude failure in sampling.
Due to the fact that the detection limit and PCR effi-
ciency of the E-Gene assay and the orf1ab assay are nearly 
identical, as determined by probit analyses, we recom-
mend running both PCR 1 and PCR 2 as "duplicate-like" 
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assays to save patient material and PCR consumables, 
increasing the sample throughput at the same time. Addi-
tionally, the use of two individual PCRs in two wells of 
the same PCR plate instead of commonly used duplicates 
draws attention to pipetting errors or other unexpected 
discrepancies by keeping a conformational approach. Fig-
ure 1 summarizes the principle of the RKI/ZBS1 SARS-
CoV-2 protocol.
In silico validation of the SARS‑CoV‑2 PCR assays
With the increasing number of genomic sequences 
deposited in public databases like GISAID, the primers 
and probes applied for SARS-CoV-2 detection in PCR 1 
and PCR 2 were subjected to controls by aligning the oli-
gonucleotide sequences to full genome alignments of all 
available SARS-CoV-2 genome sequences. Common PCR 
design rules were applied to assess the validity of the PCR 
assays [11, 12].
Reaction conditions
The presented RKI/ZBS1 SARS-CoV-2 protocol has been 
established, validated and subsequently used in routine 
diagnostics with the following workflow. RNA extracted 
by the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, 
Germany) and PCR performed with the AgPath-ID™ 
One-Step RT-PCR Reagents kit (Applied Biosystems, 
Foster City, CA, USA) on a Bio-Rad CFX96 real-time 
PCR cycler. Cycling conditions were set as follows: 45 °C 
for 15  min, 95  °C for 10  min followed by 45 cycles of 
95 °C for 15 s and 60 °C for 30 s. Total runtime was about 
95 min. PCR mix composition is shown in Tables 3 and 
4. As positive controls genomic SARS-CoV-2 RNA and 
genomic SARS-CoV RNA were used for the orf1ab and 
the E-Gene assay, respectively, and adjusted to CT 28 and 
32.
To assess the performance of further commercially 
available one-step RT-PCR master mixes with the RKI/
ZBS1 SARS-CoV-2 protocol, 10 clinical specimens 
with varying viral genome load were analyzed with the 
AgPath-ID master mix on the Bio-Rad CFX96 cycler 
and compared to the SuperScript™ III One-Step RT-
PCR System with Platinum™ Taq DNA Polymerase 
(Invitrogen, Carlsbad, CA, USA), the lyophilized 1-step 
RT-PCR Polymerase Mix (TIB MOLBIOL, Berlin, Ger-
many), the TaqPath™ 1-Step Multiplex Master Mix (No 
ROX) (Applied Biosystems), two kits from Solis BioDyne 
Table 1 Primers and probes for PCR 1: E-Gene/KoMa
a Orientation
b Position in GenBank entry (E_Sarbeco: Acc# NC_004718)
c Thermodynamic melting temperature
d Artificial sequence
* Corman et al.
Name Sequence Oa Positionb Tmc
E_Sarbeco_F1* ACAggTACgTTA ATA gTTA ATA gCgT S 26,141 53.9
E_Sarbeco_R2* ATATTgCAgCAgTACgCAC ACA A 26,232 57.9
E_Sarbeco_P1* FAM-ACA CTA gCCA TCC TTACTgCgCTTCg-BHQ1 S 26,204 65.0
KoMa F ggTgATgCCgCAT TAT TACTAgg S n/ad 57.8
KoMa R ggTATTAgCAgTCgCAggCTT A n/ad 57.8
KoMa TM TexRed-TTCTTgCTTgAggATCTgTCgTggATCg-BBQ S n/ad 67.7
Table 2 Primers and probes for PCR 2: orf1ab/c-myc
a Orientation
b Position in GenBank entry (orf 1ab: Acc# MN997409.1; c-myc NM_002467.6, GeneID: 4609)
c Thermodynamic melting temperature
* Corman et al. [6]
Name Sequence Oa Positionb Tmc
orf1ab S CTCTggAAC ACT TTT ACA AgACTTC S 19,608 54.5
orf1ab A ACC ATC AAC TTT TgTgTAA ACA gTg A 19,754 56.3
orf1ab TMGB FAM-ACAgggTgAAgTACCA-MGB S 19,688 66.0
c-myc F TAgTggAAA ACC AgCAgCCT S 380 57.0
c-myc R TCgTCgCAgTAgAAA TAC gg A 488 56.0
c-myc TM Cy5-TATgACCTCgACTACgACTCggTgC-BBQ S 442 63.5
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(SOLIScript 1-step Multiplex Probe Kit, SOLIScript® 
1-step CoV Kit; Solis BioDyne, Tartu, Estonia) and the 
GoTaq® Probe 1-Step RT-qPCR System (Promega, Wall-
dorf, Germany). All PCR reagents were used according 
to the manufacturers’ instructions, with the exception 
of 5  µl of template used for all kits for better compara-
bility. When 10  µl of template were recommended, the 
reaction volume was substituted with water. In addition, 
five popular real-time PCR cyclers were compared with 
the same specimen panel by using the standard protocol 
based on the AgPath-ID kit shown above. These cyclers 
included: the Bio-Rad CFX96 (CFX96 Touch Real-Time 
PCR Detection System), the AB7500 (7500 Real-Time 
PCR System, Applied Biosystems), the AB Quantstu-
dio 5 (QuantStudio 5 Real-Time PCR System, Applied 
Biosystems), the LC480 (LightCycler® 480 Instrument 
II, Roche, Mannheim, Germany) and the Rotor-Gene 
(Rotor-Gene Q 5plex Platform, Qiagen).
Fig. 1 Principle of the RKI/ZBS1 protocol for the real-time PCR detection of SARS-CoV-2. RKI/ZBS1 SARS-CoV-2 protocol
Table 3 Master mix PCR reaction 1 E-Gene/KoMa




2× RT-PCR buffer 12.50
nCoV E_Sarbeco F1 (10 µM) 1.00
nCoV E_Sarbeco R2 (10 µM) 1.00
E_Sarbeco P1 FAM (10 µM) 0.50
KoMa F (10 µM) 0.75
KoMa R (10 µM) 0.75
KoMa TM TexRed (10 µM) 0.25




Table 4 Master mix PCR reaction 2 orf1ab/c-myc




2× RT-PCR buffer 12.50
orf1ab S (10 µM) 0.75
orf1ab A (10 µM) 0.75
orf1ab TMGB (10 µM) 0.25
c-myc F (10 µM) 0.3
c-myc R (10 µM) 0.3
c-myc TM Cy5 (10 µM) 0.25
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Specificity testing
Specificity of the E-Gene assay has already been shown 
in the original publication [6]. Specificity of the orf1ab 
PCR assay in PCR 2 was assessed with several clinical 
specimens from patients with respiratory infections as 
well as cell culture supernatant of relevant viruses (for 
details see results section). These specimens showed 
CT values between 10 and 22 with virus-specific assays.
Limit of detection
Probit analyses [13] were performed for the uniplex 
E-Gene and orf1ab PCR, respectively, in direct compar-
ison to the duplex PCR 1, E-Gene/KoMa, and PCR 2, 
orf1ab/c-myc. Dilutions of SARS-CoV-2 genomic RNA 
were quantified by comparison to in  vitro RNA pre-
pared in a background of SARS-CoV-2-negative patient 
swab material to simulate typical amounts of human 
nucleic acid background, extracted and subjected to the 
uniplex SARS-CoV-2 assays and the duplex PCR assays 
PCR 1 and PCR 2. Duplicates were run for clearly 
detectable virus amounts down to 75 genome copies 
per reaction, while tenfold replicates were run for con-
centrations below this.
KoMa virus‑like particle (VLP) production
KoMa VLPs were generated according to standard pro-
tocols with minor specific modifications (to be pub-
lished elsewhere). The protocol including the sequence 
as well as limited amounts of VLPs containing the 
KoMa sequences can be provided to interested parties 
on request. The Qiagen (QIAamp Viral RNA Mini QIA-
cube Kit) extraction protocol included 5 µL of KoMa 
VLP suspension added to AVL buffer prior to adding 
of the specimen. Following extraction, the expected CT 
value for KoMa is in the range of 32 in PCR 1 (E-Gene/
KoMa). FCS spiked with KoMa was extracted to define 
the actual reference value and to control the VLP 
quality.
Clinical specimens
Dry or wet nasopharyngeal and/or oropharyngeal swabs 
were sent to the Robert Koch Institute for PCR diagnos-
tics. Wet swabs were kept in transport media, dry swabs 
were transferred to 500 µL of PBS. If two swabs arrived 
for one person, liquid for extraction was pooled. All 
swabs were vortexed and spun down prior to extraction 
of 140  µl of the specimen, by using the QIAamp Viral 
RNA Mini Kit and QIAcube Connects with the manual 
lysis protocol. Remaining specimen volume was stored at 
− 40 to − 80 °C.
Results
Specificity and limit of detection
Information regarding the E-Gene assay analytical speci-
ficity can be taken from [6]. Analytical specificity test-
ing for the SARS-CoV-2 orf1ab uniplex assay showed no 
reactivity for SARS-CoV (cell culture n = 1), MERS-CoV 
(cell culture n = 1), NL63, OC43, 229E (each cell culture 
n = 1) and patient samples infected with parainfluenza 
virus 1 (n = 15) and 4 (n = 4), rhinovirus (n = 20), influ-
enzavirus A (H1N1 n = 1, H3N2 n = 20), influenzavirus B 
(n = 1), adenovirus (various, n = 20), human metapneu-
movirus (n = 20) and respiratory syncytial virus (n = 17) 
when tested in high viral loads of CT values between 10 
and 22.
In addition, due to the fact that not all new SARS-
CoV-2 variants can be tested in practice, the RKI/ZBS1 
SARS-CoV-2 protocol was validated in silico twice a 
week. Of the 76,312 high-coverage genome sequences 
acquired from the GISAID  database (on Oct 15, 2020), 
primer and probe mismatches could be identified in 2% 
of the sequences, rarely in essential positions, indicating 
the assay’s functionality for the vast majority of circulat-
ing viruses. However, a regular control for the region-
ally circulating viruses with primer and probe adaption 
is strongly recommended, as long as the changes do 
not conflict with the assay’s reaction temperature and 
specificity.
By probit analysis the limit of detection for the uniplex 
E-Gene assay under the described standard reaction con-
ditions (AgPath-ID PCR kit, BioRad CFX96) was deter-
mined as 6.4 genome copies per reaction in comparison 
to 9.8 genome copies in the duplex E-Gene/KoMa PCR 
1. For the orf1ab assay the probit analysis revealed 6.6 
genome copies per reaction for both the uniplex PCR and 
the duplex orf1ab/c-myc PCR 2. When comparing the 
results obtained for the orf1ab assay to the results gen-
erated by the E-Gene assay, which can be considered as 
reference, for 424 SARS-CoV-2-positive specimens, the 
sensitivity of the orf1ab assay was 97.6%, the specificity 
99.8%, the positive predictive value 98.8% and the nega-
tive predictive value 99.7%.
Additional file 1: Figure S1 shows the correlation of the 
CT values obtained for 407 specimens positive for the 
E-Gene PCR with the orf1ab PCR. Shown is the correla-
tion over all specimens (blue line,  R2 = 0.94), the corre-
lation for specimens with E-Gene PCR CT values below 
CT = 33 (red line,  R2 = 0.95) and finally also for speci-
mens with E-Gene PCR CT values above CT = 33 (green 
line,  R2 = 0.33).
Moreover, the established RKI/ZBS1 SARS-CoV-2 pro-
tocol was compared to the RealStar® SARS-CoV-2 RT-
PCR Kit 1.0 (Altona Diagnostics, Hamburg, Germany) 
and the EURORealTime SARS-CoV-2 (EuroImmun, 
Page 6 of 11Michel et al. Virol J          (2021) 18:110 
Lübeck, Germany) with 10 clinical specimens described 
below. Differences in CT values were < 0.2 when com-
paring the RKI/ZBS1 SARS-CoV-2 protocol with the 
commercially available kits, indicating highly similar 
detection capabilities.
Experience from routine application of the RKI/ZBS1 
SARS‑CoV‑2 protocol
The presented RKI/ZBS1 SARS-CoV-2 protocol aims at 
a high sample throughput with resource-friendly rea-
gent consumption. Therefore, we did not run dupli-
cates per reaction (PCR 1: E-Gene/KoMa and PCR 2: 
orf1ab/c-myc), but instead treated the results of the two 
different SARS-CoV-2 assays, E-Gene and orf1ab, like a 
duplicate. Figure  2 displays the results of the first 3600 
naso- and oropharyngeal specimens analyzed with the 
RKI/ZBS1 SARS-CoV-2 protocol. Red icons show the 
CT values obtained for 424 SARS-CoV-2-positive speci-
mens (11.8%) with a difference of mean CT values of 
30.5 [± 5.4] for the PCR 1 and 30.9 [± 5.3] for the PCR 2. 
Negative samples are displayed as CT 45 since PCR is run 
for 45 cycles; however, the value of 45 is not used for any 
calculation.
Furthermore, Fig.  2 shows that the CT values for 
the nucleic acid control c-myc in PCR 2 are scattered 
between CT 20 and CT 44, reflecting the varying nucleic 
acid content of the swab samples. Only 90 out of 3600 
specimens (2.5%) were negative for c-myc, with 8/90 
being clearly positive for SARS-CoV-2, making the c-myc 
result obsolete. The remaining 82 c-myc-negative sam-
ples can probably be attributed to inefficient swabbing.
The mean KoMa CT value of the KoMa-positive sam-
ples is in the expected range of 32.3 ± 1.4. Figure 3 shows 
the general principle of the KoMa control. While highly 
positive SARS-CoV-2 specimens with CT values < 20 
and < 25 showed either no or only 70% KoMa positives, 
respectively, a decreasing SARS-CoV-2 genome load 
(CT > 25) led to a significantly higher positivity rate for 
KoMa detection (p < 0.0001). Of the SARS-CoV-2-nega-
tive specimens, only 0.3% failed to amplify KoMa, point-
ing to PCR inhibition or extraction failure. This is most 
important, since in qualitative settings, like the one 
described above, samples that are clearly positive for 
SARS-CoV-2 do not need confirmation by the inhibi-
tion control. Only samples that are negative or borderline 
positive for SARS-CoV-2 require proof that the PCR is 
not inhibited and RNA extraction was efficient.
Fig. 2 CT value overview for 3600 clinical specimens tested with the RKI/ZBS1 SARS-CoV-2 protocol. CT values for the four PCR assays included in 
the RKI/ZBS1 SARS-CoV-2 protocol as determined for the first 3600 specimens. Red symbols show the SARS-CoV-2 assays (negatives not shown), 
blue squares the inhibition control KoMa and green circles the nucleic acid detection by c-myc amplification. The constant detection of the 
inhibition control KoMa can be seen, and the scattering of the nucleic acid content demonstrated by c-myc as well as the similar CT values for the 
E-Gene and the orf1ab assay
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Challenges of result interpretation
The huge majority of approximately > 98% of the ana-
lyzed specimens gave clear-cut results after the first run, 
either negative or positive. However, to facilitate result 
interpretation for ambiguous results, Table 5 summarizes 
the possible constellations together with the proposed 
required measure for confirmation. Assuming that the 
amplification curves are real amplification curves, even 
appearing late or low, the following scheme was referred 
to for result interpretation.
If the RKI/ZBS1 SARS-CoV-2 protocol is repeated 
with 10 µl of template RNA according to the scheme in 
Table  5, for “real” PCR results (contrasted to PCR arti-
facts) a shift by approximately one CT value is expected.
The RKI/ZBS1 SARS‑CoV‑2 protocol can be used 
with several PCR reagent kits and real‑time PCR cyclers
We tested a selection of 10 clinical specimens on five 
popular real-time PCR cyclers as listed in the Mate-
rial section. Figure  4 displays the CT values obtained 
on the different instruments for the E-Gene, the orf1ab, 
the KoMa and the c-myc assays. Even if a statistically 
sound conclusion cannot be drawn from these resource-
friendly generated data, it can be assumed that for virus 
loads with CT values below 35 the differences for SARS-
CoV-2 detection are marginal between the cyclers. It 
can be assumed that the Rotor-Gene copes better with 
the orf1ab assay than with the E-Gene assay, as shown 
by a detection that was by 1–2 CT values lower for the 
same specimens. For the LC480 this effect is less distinct. 
Lower virus loads lead to CT scattering between differ-
ent instruments as expected for statistical reasons. How-
ever, no clear trend towards one or the other cycler can 
be observed when assessing the virus detection.
Evaluating the control assays KoMa and c-myc, it is 
peculiar that the Rotor-Gene is able to detect KoMa as 
well as c-myc in all 10 clinical specimens, independent 
of the viral genome amount amplified in the duplex PCR 
reactions. All other instruments show dropouts in the 
control reactions.
Fig. 3 Correlation between the internal KoMa control and 
SARS-CoV-2 genome load in clinical specimens. For the 424 
SARS-CoV-2-positive specimens the CT values were grouped as 
indicated and plotted against the CT value for the inhibition control 
KoMa. While in specimens that are highly positive for SARS-CoV-2 
KoMa does not give a signal reliably, in specimens with genome 
loads close to the detection limit as well as in negative samples, 
KoMa is constantly amplified, showing the efficiency of the nucleic 
acid extraction and possible inhibitory effects of the sample matrix. 
Detectability increases significantly with E-Gene CT values higher 
than 25 (Mann Whitney p < 0.0001)
Table 5 Interpretation of results obtained with the RKI/ZBS1 SARS-CoV-2 protocol
Besides clearly positive and clearly negative results showing the controls as expected, unequivocal results can be obtained in particular with low concentrations of 
viral RNA. Measures for confirmation of such results are described in the table
* If ΔCT value is > 3 repeat PCR with 10 µl of RNA template
SARS‑CoV‑2 Inhibition control Nucleic acid control Result Comments
# E‑Gene orf1ab KoMa c‑myc
1  < 38  < 38 Any Any Positive
2  < 38*  ≤ 45* 32 ± 3 Signal Positive
3  ≤ 45*  < 38* 32 ± 3 Signal Positive
4  ≥ 38  ≥ 38 32 ± 3 Any Ambiguous if curves are distinctly positive; if 
not, analyze follow-up sample
5 Signal Negative 32 ± 3 Signal repeat PCR with 10 µl
6 Negative Signal 32 ± 3 Signal repeat PCR with 10 µl
7 Negative Negative 32 ± 3 Negative Invalid analyze follow-up sample
8 Negative Negative  > 35 Any Invalid repeat extraction with 1:10 dilution
9 Negative Negative 32 ± 3 Signal Negative
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The runtime of the RKI/ZBS1 SARS-CoV-2 protocol 
for the different instruments was 92  min for the Bio-
Rad CFX96, 90 min for the AB7500, 90 min for the AB 
Quantstudio 5, 95 min for the LC480 and 111 min for the 
Rotor-Gene.
PCR master mixes
Seven one-step RT-PCR master mixes were compared 
with the RKI/ZBS1-SARS-CoV-2 protocol. As shown 
in Fig. 5, up to CT 35 all kits perform comparably, with 
the exception of the SuperScript™ III One-Step RT-PCR 
System with Platinum™ Taq DNA Polymerase and the 
GoTaq® Probe 1-Step RT-qPCR System. The first one 
shows slightly increased CT values with the E-Gene assay 
in PCR 1 and clearly increased CT values for the orf1ab 
assay in PCR 2. The second one gives slightly higher CT 
values for both SARS-CoV-2 assays. For specimens con-
taining only very low virus amounts, no clear conclusion 
can be drawn. For one specimen tested negative several 
times also with various master mixes, a low positive sig-
nal of CT 38.5 could be observed with the TIB MOL-
BIOL reagent. Similar results occurred occasionally with 
the E-Gene assay in PCR 1 independently of the reaction 
conditions, but could be clarified by comparison with 
the orf1ab assay in PCR 2 according to Table  5. Finally, 
as observed in the cycler comparison, the duplexed con-
trol assays KoMa and c-myc seem to be more susceptible 
to the master mix under the applied standard reaction 
conditions. The lyophilized 1-step RT-PCR Polymerase 
Mix (TIB MOLBIOL) and the SOLIScript® 1-step CoV 
kit can amplify the KoMa control even in specimens 
highly positive for SARS-CoV-2, even with higher CT 
values than expected. Similarly, the duplexed c-myc assay 
seems to be more sensitive, with these reagents being 
positive in ten out of ten specimens with the SOLIScript® 
1-step CoV kit, while the SuperScript™ III One-Step 
RT-PCR System with Platinum™ Taq DNA Polymerase 
amplifies c-myc only in two out of ten specimens from 
the same specimens.
Discussion
In this study we developed a protocol that can be con-
sidered as a robust alternative to available protocols. 
This RKI/ZBS1 SARS-CoV-2 protocol detects two dif-
ferent SARS-CoV-2 genomic regions in independent 
reactions. The E-Gene assay has already been pub-
lished; the orf1ab assay was established and validated 
in this study. Each of the SARS-CoV-2 assays is com-
bined with a control in a duplex reaction that enables 
either inhibition control or efficient sampling, respec-
tively. Especially for SARS-CoV-2-negative specimens 
these controls are crucial for reporting a reliable result. 
Hence, the inhibition control KoMa was established to 
give a signal in negative and low positive specimens. In 
highly positive SARS-CoV-2 specimens KoMa is not 
amplified, which is acceptable since clearly positive 
Fig. 4 RKI/ZBS1 SARS-CoV-2 protocol performance on different PCR cyclers. To show that the presented protocol can be run on several cyclers, 
we used 10 clinical samples of different RNA load, negative as well as positive controls and set up one master mix that was distributed to the 
different cyclers as shown above. Different colors represent 10 different samples used for comparison. Mean values of duplicates are shown, also for 
SARS-CoV-2-positive controls (crosses); negative controls are not shown
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specimens do not require a proof of an unaffected PCR 
reaction in a qualitative setting. The c-myc assay was 
selected after testing several known "reference genes", 
including assays that exclusively amplify RNA and not 
genomic DNA [14]. Unfortunately, we observed that 
RNA-specific assays became positive in 50%–70% of 
the analyzed specimens. Based on the available data, we 
could not find a correlation to swab types, sampling site 
or SARS-CoV-2 positivity. In contrast, a considerable 
proportion of SARS-CoV-2-positive specimens were 
negative in the RNA control assay to indicate presence 
of RNA. It was assumed that the tested assays were not 
sensitive enough to amplify the amounts of cellular 
mRNA in the investigated specimens that were some-
times extremely low, possibly due to the denaturation 
of free cellular RNA at room temperature [15]. There-
fore, we redesigned the control PCR to amplify RNA 
as well as DNA. With this assay we succeeded in show-
ing correct sampling for 97.5% of the 3600 specimens 
described here.
Notably, even if real-time PCR is generally able to pro-
vide quantitative results, it is not possible to quantify 
SARS-CoV-2 from swab specimens. As demonstrated by 
the varying CT values for c-myc, swabs do not permit a 
standardization that could be used as reference for quan-
tification, such as the one that blood, urine or other bod-
ily fluids can provide via the volume. Hence, quantitative 
results should not be expected from PCR diagnostics of 
swabs.
The comparison of five common real-time PCR cyclers 
with the standard protocol showed that for SARS-CoV-2 
loads of up to CT 35 no significant differences could be 
observed. They can be dependent on the assay, as the 
Rotor-Gene was providing CT values that were 1–2 units 
lower for the orf1ab assay compared to other instru-
ments, but not for the E-Gene assay. However, even if a 
full statistical evaluation with multiple repetitions may be 
required to reveal minor variances for virus specimens 
at low concentrations, it can be hypothesized that, at 
least after careful adaption of the reaction conditions, all 
cyclers are suitable for SARS-CoV-2 detection with the 
primers and probes presented. More striking differences 
could be observed regarding the ability to amplify the 
duplexed control reactions KoMa and c-myc. Here, the 
Rotor-Gene was the only instrument to amplify KoMa 
as well as c-myc in the respective duplex PCR assays, 
regardless of the virus concentration in the specimen. 
Since the control reactions were established with low 
primer and probe concentrations to reduce the impact 
on the virus detection, the Rotor-Gene seems to manage 
best these sub-optimal reaction conditions.
However, in addition to the detection limit, several 
other factors have to be considered to select the proper 
real-time PCR cycler, such as availability, costs for the 
acquisition and the consumables as well as practical 
questions of workflow automation [16, 17].
For the master mix comparison seven reagents were 
selected. As reference the routinely used AgPath-ID™ 
Fig. 5 RKI/ZBS1 SARS-CoV-2 protocol performance with different PCR master mixes. In total 7 PCR mixes were compared with the RKI/ZBS1 
SARS-CoV-2 protocol on a Bio-Rad CFX96 cycler. 10 clinical specimens of different RNA load and negative as well as positive controls were set up. 
Means of duplicate CT values are plotted against the respective master mix. Positive controls (crosses) are shown only for the SARS-CoV-2 assays 
E-Gene and orf1ab; negative controls are not shown
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One-Step RT-PCR Reagents kit (Applied Biosystems) 
was compared to three master mixes that are supposed 
to be stable at room temperature for one to four weeks, 
promising good handling even in laboratories not able to 
provide constant cold chains, from TIB MOLBIOL and 
Solis BioDyne, as well as commonly used master mixes 
listed in the material section. For viral loads with CT 
values below 35 most kits performed comparably well. 
Interestingly, with the E-Gene assay the SuperScript™ 
III One-Step RT-PCR System with Platinum™ Taq DNA 
Polymerase generated similar CT values to most of the 
other kits, but showed clearly elevated CT values for all 
other assays, orf1ab, KoMa and c-myc. There is no obvi-
ous similarity between these three assays, except that 
they run with lower primer and probe concentrations 
than the E-Gene assay. Moreover, even when the GoTaq® 
Probe 1-Step RT-qPCR System showed slightly elevated 
CT values for all four assays there was no assay-specific 
effect, and all SARS-CoV-2-positive specimens were 
identified correctly. As shown in Fig. 5, the control reac-
tions KoMa and c-myc were less often amplified with 
the SuperScript™ III One-Step RT-PCR System with 
Platinum™ Taq DNA Polymerase and showed higher CT 
values than other master mixes did. It can be speculated 
that these master mixes require higher primer and probe 
concentrations or are not composed to run duplex PCRs. 
However, no total failure was observed for any of the 
tested kits as had been surprisingly observed previously 
in other settings [18]. The yield in amplifying the controls 
was best with the TIB MOLBIOL  and the SOLIScript® 
1-step CoV Kit.
It is important to note that beside the system-inher-
ent variability of real-time PCR, in particular in the low 
concentration range of a target, individual effects like 
the definition of the fluorescence signal threshold or the 
probe quality may have an influence on the results.
Summing up, we have established a real-time one-
step RT-PCR-based protocol that can be used to detect 
SARS-CoV-2 RNA in clinical specimens with low detec-
tion limit. By duplexing two independent SARS-CoV-2 
detection assays with an inhibition control and a nucleic 
acid control, the protocol is highly reliable regarding false 
negative samples due to sequence variation in the virus 
genome, poor sampling, extraction or PCR inhibition. 
The protocol saves reagents by running a duplicate-like 
approach and can be transferred to various real-time 
PCR instruments and PCR master mixes. Because of its 
flexibility, this protocol presents a helpful alternative to 
other solutions in times of reagent shortage.
Finally, the reliability of the RKI/ZBS1 SARS-CoV-2 
protocol could be proven by the successful participation 
in four external quality assessment studies (three times 
INSTAND, one time ECDC); results are going to be pub-
lished by the ring trial providers.
Conclusions
Although a variety of real-time PCR assays for the detec-
tion of SARS-CoV-2 has been published to date, the pre-
sented RKI/ZBS1 SARS-CoV-2 protocol shows some 
advantages. First, it detects two independent SARS-CoV-2 
genomic regions that can be used for confirmation instead 
of using duplicates of the same target. Second, it utilizes 
two controls proving the successful sampling by indicat-
ing cellular nucleic acid, which is particularly important 
for SARS-CoV-2-negative specimens, as well as inhibition 
of the PCR process. Since all four assays can be run in two 
duplex PCR reactions, the presented approach saves time 
and resources, which becomes more and more important 
in times of PCR reagent and consumable shortages.
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